Li Wen, Hu Hong
Department of Respiratory Medicine, Chinese PLA General Hospital, Beijing 100853, China.
Zhonghua Yi Xue Za Zhi. 2009 Feb 3;89(4):230-4.
To investigate the relation between bone morphogenetic protein type II receptor (BMPR2) gene promoter mutation and pulmonary arterial hypertension (PAH).
Peripheral blood samples were collected from a 36-year-old female patient with familial PAH (FPAH), 19 idiopathic PAH (IPAH) patients, and 50 healthy controls. DNA sequencing was conducted for the position -2022 bp upstream of the promoter transcription start point of BMPR2 gene. Two fragments carrying BMPR2 promoter mutation -142A and wild -142G allele were amplified and cloned respectively into the pGL3-basic dual-luciferase reporter gene vector, thus generating two luciferase reporter constructs: pGL3-BMPR2-wild recombinant plasmid (carrying -142G allele) and pGL3-BMPR2-mut recombinant plasmid (carrying -142A allele). Human pulmonary arterial smooth muscle cells (HPASMCs) and human pulmonary arterial endothelial cells (HPAECs) were cultured and transfected with pGL3-BMPR2-wild and pGL3-BMPR2-mut recombinant plasmids respectively. The transcriptional activity levels of these 2 recombinant plasmids were measured by Veritas Microplate Luminometer, and were calculated as the ratio of firefly luciferase activity to Renilla luciferase activity. The binding sites for transcriptional factors on the flanking sequence of the wild and mutant BMPR2 gene promoter regions were analyzed by using the MAPPER Search Engine.
A mutation -142G > A in the promoter region of BMPR2 gene was found in this female patient with FPAH. The transcriptional activity levels of the BMPR2 promoter carrying -142A allele in the HPASMCs and HPAECs were (9.58 +/- 3.85) and (59.07 +/- 25.54) respectively, both significantly lower than those of the BMPR2 promoter carrying -142G allele [(16.80 +/- 3.55) and (115.58 +/- 38.02) respectively, both P < 0.05]. The binding site of specificity protein 3, the potential transcriptional factor, was deleted in the BMPR2 promoter carrying -142A allele compared to the BMPR2 promoter carrying -142G allele.
BMPR2 promoter mutation -142G > A may be associated with FPAH.
探讨Ⅱ型骨形态发生蛋白受体(BMPR2)基因启动子突变与肺动脉高压(PAH)的关系。
采集1例36岁家族性PAH(FPAH)女性患者、19例特发性PAH(IPAH)患者及50例健康对照者的外周血样本。对BMPR2基因启动子转录起始点上游-2022 bp位置进行DNA测序。分别扩增携带BMPR2启动子突变-142A和野生型-142G等位基因的两个片段,并将其克隆到pGL3-basic双荧光素酶报告基因载体中,从而构建两个荧光素酶报告基因构建体:pGL3-BMPR2-野生重组质粒(携带-142G等位基因)和pGL3-BMPR2-突变重组质粒(携带-142A等位基因)。培养人肺动脉平滑肌细胞(HPASMCs)和人肺动脉内皮细胞(HPAECs),并分别用pGL3-BMPR2-野生和pGL3-BMPR2-突变重组质粒进行转染。用Veritas微孔板发光计测量这两种重组质粒的转录活性水平,并计算为萤火虫荧光素酶活性与海肾荧光素酶活性之比。使用MAPPER搜索引擎分析野生型和突变型BMPR2基因启动子区域侧翼序列上转录因子的结合位点。
在该FPAH女性患者中发现BMPR2基因启动子区域存在-142G>A突变。携带-142A等位基因的BMPR2启动子在HPASMCs和HPAECs中的转录活性水平分别为(9.58±3.85)和(59.07±25.54),均显著低于携带-142G等位基因的BMPR2启动子[分别为(16.80±3.55)和(115.58±38.02),P均<0.05]。与携带-142G等位基因的BMPR2启动子相比,携带-142A等位基因的BMPR2启动子中潜在转录因子特异性蛋白3的结合位点缺失。
BMPR2启动子突变-142G>A可能与FPAH相关。